We'll have to agree to disagree. Once you have approval I don't see how additional approvals matter, what matters is sales. Certainly approvals gain sales, but post approval it's all about sales. In that the target indication for both progression and OS is the same, I doubt if there will be a label change if they pursue approval on OS. Clearly they'll continue to gather the data, but how do you see that enhancing sales. Certainly other trials which expand use will increase sales, but again, those trials couldn't possibly have been dreamed of when the partnership was initiated, sales however were.
